IN2014DN10801A - - Google Patents

Info

Publication number
IN2014DN10801A
IN2014DN10801A IN10801DEN2014A IN2014DN10801A IN 2014DN10801 A IN2014DN10801 A IN 2014DN10801A IN 10801DEN2014 A IN10801DEN2014 A IN 10801DEN2014A IN 2014DN10801 A IN2014DN10801 A IN 2014DN10801A
Authority
IN
India
Prior art keywords
inhibitor
imatinib
gist
therapy
fgfr
Prior art date
Application number
Inventor
John E Monahan
Fang Li
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2012/061535 external-priority patent/WO2013063003A1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2014DN10801A publication Critical patent/IN2014DN10801A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to a method of treating gastrointestinal stromal tumors (GIST) especially GIST which is progressing after imatinib therapy or after imatinib and sunitinib therapy using a combination comprising (a) a c kit inhibitor and (b) a dual KIT inhibitor and FGFR inhibitor or FGFR inhibitor.
IN10801DEN2014 2012-07-11 2013-04-12 IN2014DN10801A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261670168P 2012-07-11 2012-07-11
PCT/US2012/061535 WO2013063003A1 (en) 2011-10-28 2012-10-24 Method of treating gastrointestinal stromal tumors
PCT/US2013/036273 WO2014011284A1 (en) 2012-07-11 2013-04-12 Method of treating gastrointestinal stromal tumors

Publications (1)

Publication Number Publication Date
IN2014DN10801A true IN2014DN10801A (en) 2015-09-04

Family

ID=49916465

Family Applications (1)

Application Number Title Priority Date Filing Date
IN10801DEN2014 IN2014DN10801A (en) 2012-07-11 2013-04-12

Country Status (12)

Country Link
US (1) US20150202203A1 (en)
EP (1) EP2872142A1 (en)
JP (1) JP2015522070A (en)
KR (1) KR20150036014A (en)
CN (1) CN104427986A (en)
AU (1) AU2013289175A1 (en)
BR (1) BR112015000349A2 (en)
CA (1) CA2878251A1 (en)
IN (1) IN2014DN10801A (en)
MX (1) MX2015000457A (en)
RU (1) RU2015104537A (en)
WO (1) WO2014011284A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
US9611267B2 (en) 2012-06-13 2017-04-04 Incyte Holdings Corporation Substituted tricyclic compounds as FGFR inhibitors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
TWI649318B (en) 2013-04-19 2019-02-01 英塞特控股公司 Bicyclic heterocycle as an FGFR inhibitor
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (en) 2015-02-20 2017-12-26 Incyte Corp BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS
AU2016219822B2 (en) 2015-02-20 2020-07-09 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
KR20180100227A (en) * 2016-01-11 2018-09-07 메르크 파텐트 게엠베하 Quinolin-2-one derivative
US10954044B2 (en) 2017-05-05 2021-03-23 Csp Technologies, Inc. Container having child-resistant senior-friendly features and method of using and making same
AR111960A1 (en) 2017-05-26 2019-09-04 Incyte Corp CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION
ES2991427T3 (en) 2018-05-04 2024-12-03 Incyte Corp Solid forms of an FGFR inhibitor and methods for preparing the same
TW201946630A (en) 2018-05-04 2019-12-16 美商英塞特公司 Salts of an FGFR inhibitor
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US10835531B1 (en) * 2019-06-18 2020-11-17 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021046550A1 (en) * 2019-09-06 2021-03-11 Mantra Bio, Inc. Extracellular vesicle-fenretinide compositions, extracellular vesicle-c-kit inhibitor compositions, methods of making and uses thereof
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
GEAP202415945A (en) 2019-10-14 2024-04-25 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
AU2020395185A1 (en) 2019-12-04 2022-06-02 Incyte Corporation Derivatives of an FGFR inhibitor
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP4097474A4 (en) 2020-01-27 2024-03-27 Mantra Bio, Inc. NON-NATURALLY PRODUCED VESICLES COMPRISING A CHIMERIC VESICLE LOCALIZATION FRACTION, THEIR METHODS OF MANUFACTURING AND THEIR USES
EP4323405A1 (en) 2021-04-12 2024-02-21 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
AR126101A1 (en) 2021-06-09 2023-09-13 Incyte Corp TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
CO4940418A1 (en) 1997-07-18 2000-07-24 Novartis Ag MODIFICATION OF A CRYSTAL OF A DERIVATIVE OF N-PHENYL-2-PIRIMIDINAMINE, PROCESSES FOR ITS MANUFACTURE AND USE
US20030028018A1 (en) 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
PL211125B1 (en) 2000-09-11 2012-04-30 Novartis Vaccines & Diagnostic Quinolinone derivatives as tyrosine kinase inhibitors
GB0202873D0 (en) 2002-02-07 2002-03-27 Novartis Ag Organic compounds
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
ITTV20030095A1 (en) 2003-07-14 2005-01-15 Asolo Spa FOOTWEAR WITH COMPOSITE INSOLE.
WO2005047244A2 (en) 2003-11-07 2005-05-26 Chiron Corporation Inhibition of fgfr3 and treatment of multiple myeloma
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
CN101222850B (en) * 2005-05-13 2012-10-03 诺瓦提斯公司 Ways to treat cancers that are resistant to drugs
NZ563692A (en) 2005-05-23 2011-04-29 Novartis Ag Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
GT200600316A (en) 2005-07-20 2007-04-02 SALTS OF 4-METHYL-N- (3- (4-METHYL-IMIDAZOL-1-ILO) -5-TRIFLUOROMETILO-PHENYL) -3- (4-PIRIDINA-3-ILO-PIRIMIDINA-2-ILOAMINO) - BENZAMIDA.
GT200600315A (en) 2005-07-20 2007-03-19 CRYSTAL FORMS OF 4-METHYL-N- [3- (4-METHYL-IMIDAZOL-1-ILO) -5-TRIFLUOROMETILO-PHENYL] -3- (4-PYRIDINA-3-ILO-PIRIMIDINA-2-ILOAMINO) -BENZAMIDA
PL1957074T3 (en) 2005-11-29 2014-08-29 Novartis Ag Formulations of quinolinones
EP1923053A1 (en) 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
AR070924A1 (en) 2008-03-19 2010-05-12 Novartis Ag CRYSTAL FORMS AND TWO SOLVATED FORMS OF LACTIC ACID SALTS OF 4- AMINO -5- FLUORO-3- (5- (4-METHYLIPIPERAZIN-1-IL) -1H- BENCIMIDAZOL-2-IL) QUINOLIN -2- (1H) - ONA
MY155535A (en) 2008-05-23 2015-10-30 Novartis Ag Derivatives of quinolines and quinoxalines as protien tyrosine kinase inhibitors
UY33472A (en) 2010-06-30 2012-01-31 Novartis Ag ? PHARMACEUTICAL COMPOSITIONS THAT INCLUDE 4-AMINO-5-FLUORO-3- LACTATE MONOHIDRATE [6- (4-METHYL-PIPERAZIN-1-IL) -1HBENCIMIDAZOL-2-IL] -1H-QUINOLIN-2-ONA ?.
CN103889422A (en) * 2011-10-28 2014-06-25 诺华股份有限公司 Method of treating gastrointestinal stromal tumors

Also Published As

Publication number Publication date
BR112015000349A2 (en) 2017-06-27
MX2015000457A (en) 2015-04-08
CN104427986A (en) 2015-03-18
EP2872142A1 (en) 2015-05-20
US20150202203A1 (en) 2015-07-23
RU2015104537A (en) 2016-08-27
AU2013289175A1 (en) 2015-01-22
JP2015522070A (en) 2015-08-03
WO2014011284A1 (en) 2014-01-16
KR20150036014A (en) 2015-04-07
CA2878251A1 (en) 2014-01-16

Similar Documents

Publication Publication Date Title
IN2014DN10801A (en)
TN2014000093A1 (en) Method of treating gastrointestinal stromal tumors
IL291000A (en) Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
PH12017501817B1 (en) Heterocyclic compounds as lsd1 inhibitors
ZA201605715B (en) Cyclopropylamines as lsd1 inhibitors
PT3418281T (en) Compounds useful as inhibitors of atr kinase for the treatment of cancer diseases
SI2646432T1 (en) Substituted benzopyrazin derivatives as fgfr kinase inhibitors for the treatment of cancer diseases
EP3094752A4 (en) Use of parp inhibitors to treat breast or ovarian cancer patients showing a loss of heterozygosity
JO2788B1 (en) Amidophenoxyindazoles useful as inhibitors of c-met
SG11201405574UA (en) 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors
PH12012502485A1 (en) Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors
ZA201103476B (en) Heterocyclically substituted aryl compounds as hif inhibitors
IL234640B (en) Treatment of cancer with tor kinase inhibitors
ZA201406706B (en) Treatment of cancer with tor kinase inhibitors
SG11201405686PA (en) Treatment of cancer with tor kinase inhibitors
IL234641A0 (en) Treatment of cancer with tor kinase inhibitors
TN2012000469A1 (en) Use of novel pan-cdk inhibitors for treating tumors
SG11201601150WA (en) Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors
PL2817286T3 (en) Kinase inhibitors for the treatment of cancer
IL215199A0 (en) Thia-triaza-cyclopentazulenes as pi3-kinases inhibitors for the treatment of cancer
TN2011000013A1 (en) Amidophenoxyindazoles useful as inhibitors of c-met
AU2012901199A0 (en) Kinase inhibitors for the Treatment of Cancer